PERT-IJS (pertuzumab biosimilar)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for PERT-IJS (pertuzumab biosimilar), covering 2026-03-13 to 2026-03-13. Get the full timeline:
Most recent: Clinical Trial Update: Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer [Phase 3]